Dose and regimen of subsequent radiotherapy and adjuvant chemotherapy is stratified according to age and clinical risk; patients with established high-risk disease features (metastatic disease, large cell/anaplastic histology (LCA), MYC amplification, MYCN amplification and/or TP53 mutation in SHH tumours) receive intensified therapies.6 Here, MYCN is linked to metastatic neoplasm.